Clinical Trials Logo

Filter by:
NCT ID: NCT05023980 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia

A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

BRUIN CLL-313
Start date: September 23, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305; Arm A) compared to BR (Arm B) in patients with CLL/SLL who have not been treated. Participation could last up to five years.

NCT ID: NCT05023551 Active, not recruiting - Clinical trials for Glioblastoma Multiforme

Study of DSP-0390 in Patients With Recurrent High-Grade Glioma

Start date: September 8, 2021
Phase: Early Phase 1
Study type: Interventional

This is a study of DSP-0390 in patients with recurrent high grade glioma.

NCT ID: NCT05023070 Active, not recruiting - Healthy Clinical Trials

Investigation of the Pharmacokinetic Profile of CBD

Start date: July 22, 2021
Phase: Phase 1
Study type: Interventional

The goal of the current study is to evaluate the bioavaibiltiy of CBD in normal healthy Individuals. This is an open cross-over design study in healthy individuals to assess the safety and pharmacokinetic (PK) effects of cannabidiol.

NCT ID: NCT05022901 Active, not recruiting - Clinical trials for Metastatic Uveal Melanoma

An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma

Start date: June 10, 2022
Phase: Phase 3
Study type: Interventional

Patients in the study will be treated with Melphalan/HDS and will receive up to 6 total treatments. This study will evaluate the safety and effects of the treatment.

NCT ID: NCT05022849 Active, not recruiting - Prostatic Neoplasms Clinical Trials

A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants

Start date: September 28, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine recommended Phase 2 dose (RP2D) regimen(s) of JNJ-75229414 in Part 1 (Dose Escalation and to determine safety at the RP2D regimen(s) in Part 2 (Dose Expansion).

NCT ID: NCT05022316 Active, not recruiting - Hypertension Clinical Trials

COHERE - COntextualized Care in cHcs' Electronic Health REcords

COHERE
Start date: September 12, 2022
Phase: N/A
Study type: Interventional

This study was designed to develop and test clinical decision support (CDS) tools that present clinical care team members with a given patient's social risk information and recommend care plan adaptations based on those risks. This study will test the hypothesis that providing care team members with CDS about patients' known social risks will result in improved outcomes. This study's primary outcomes are hypertension and diabetes control, but the results will have implications for a wide range of morbidities.

NCT ID: NCT05021536 Active, not recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment

Phoenix
Start date: October 28, 2021
Phase: Phase 3
Study type: Interventional

The Phoenix Trial is a randomized double blind placebo controlled Phase III trial to evaluate the safety and efficacy of AMX0035 for treatment of ALS

NCT ID: NCT05021133 Active, not recruiting - Lung Cancer Clinical Trials

Tele-Navigation of Lung Cancer Screening (Tele-Navi LCS)

Start date: June 5, 2023
Phase: N/A
Study type: Interventional

Adherence to annual follow up is critical to achieving mortality benefits and optimizing cost-effectiveness of lung cancer screening (LCS). However, adherence to LCS follow-up in the real world is suboptimal. Using telehealth, the investigators will co-create Tele-Navigation of Lung Cancer Screening with patients and LCS stakeholders as an intervention to promote adherence of follow-up LCS. The investigators will then implement the Tele-Navi LCS intervention to a pilot sample of patients and evaluate its feasibility in the primary care setting. The investigators will measure the number of patient participants who completed Tele-Navi LCS and follow-up LCS within 180 days from Tele-Navi LCS.

NCT ID: NCT05020951 Active, not recruiting - Clinical trials for Accurate and Complete Data Acquisition for Clinical Trials

Pilot Study to Enable Electronic Laboratory Data Transfer From Participating Institutions to MediData/RAVE

Start date: August 28, 2021
Phase:
Study type: Observational

An initial step toward more accurate and complete data acquisition for clinical trials, the Pediatric Early Phase Clinical Trials Network (PEP-CTN) and Pediatric Brain Tumor Consortium (PBTC) will assess the feasibility of electronic transfer of laboratory data from participating institutions' local electronic health records to the Medidata/RAVE that is housed within each consortium's Uniform Resource Locator (URL). This study will assess efficiency, effectiveness, and scalability of the laboratory data extraction and transfer processes. This study will identify factors in the process that impact consortium operations, central protocol activation and implementation to the point of declaring the site data-ready.

NCT ID: NCT05020496 Active, not recruiting - Skin Diseases Clinical Trials

Trem-1 and Ultraviolet Radiation-induced Immune Suppression

Start date: March 21, 2022
Phase: Early Phase 1
Study type: Interventional

The overall goal of this study is to determine novel mechanisms for ultraviolet light (UV)-induced suppression of the immune system in human subjects and to improve understanding of UV-induced skin carcinogenesis.